Last updated: February 20, 2026
What Is the Scope of EP2833944?
Patent EP2833944 primarily claims a pharmaceutical composition comprising a specific combination of active ingredients for treating particular medical conditions. Its scope is defined through claims covering the composition, the method of use, and specific formulations.
Key Elements of the Claims
-
Active Ingredients: The patent claims a combination including a cannabinoid compound, such as cannabidiol (CBD), optionally along with a secondary agent like THC.
-
Medical Use: The claims specify treatment of multiple conditions, such as epilepsy, neurodegenerative disorders, or chronic pain.
-
Formulation Parameters: Several claims cover formulations including oral, topical, or inhalable forms, with specific dosages or concentration ranges.
Claim Structure Breakdown
| Claim Type |
Content |
Description |
| Independent claims |
Cover the composition and methods |
Broad coverage of compositions containing CBD or similar cannabinoids; methods involve administration to treat specified conditions |
| Dependent claims |
Specify formulations, dosages, or additional features |
Narrower scope, including specific dosage ranges (e.g., 10-30 mg/kg), formulation types, or administration protocols |
Scope Limitations
- The patent’s scope explicitly excludes compositions containing other unrelated active compounds.
- It encompasses both human and veterinary uses.
- Claims covering methods involve particular routes of administration, which limit infringement possibilities to those implementing these specific methods.
What Does the Patent Landscape Look Like?
Priority and Filing Timeline
- Priority filed: May 14, 2014, based on an earlier application in the United Kingdom.
- Grant date: June 17, 2015.
- Expiration: Expected around May 14, 2034, considering the 20-year term from the earliest filing date, with potential extensions or adjustments.
Related Patent Families and Applications
- European Patent Family: EP2833944 is part of a broader family, with counterparts filed in the U.S. (US20160094759A1), Australia, and Canada.
- Scope Expansion: Some family members include claims directed at specific delivery devices, formulations, or treatment regimens to broaden protection.
Key Competitors and Relevant Patents
- Several patents exist that cover cannabinoids' medical use, notably:
| Patent |
Jurisdiction |
Filing Date |
Focus |
Assignee |
| US Patent 9205563 |
US |
2011 |
CBD for neuroprotection |
GW Pharmaceuticals |
| WO2016156915 |
WO |
2015 |
Cannabinoid formulations |
Insys Therapeutics |
| EP2905098 |
EP |
2014 |
Cannabinoid-based analgesics |
Tilray |
- EP2833944's scope overlaps with these patents, especially regarding medical indications and formulations.
Patentability and Patent Landscape Considerations
- The claims are supported by a substantial body of scientific literature supporting cannabinoids' efficacy for neurological disorders.
- Prior art includes earlier patents, clinical trials disclosures, and natural product disclosures, which could affect patent novelty or inventive step.
Legal and Commercial Implications
- The patent's broad claim scope offers significant exclusivity in Europe for cannabinoid-based treatments.
- Ongoing challenges might arise from prior disclosures or clinical research published before the filing date.
- Patent infringement risks exist when competitors develop similar formulations, especially if claims are broad and specific to active compounds and indications.
Summary
EP2833944 claims a composition comprising cannabinoids, notably CBD, for treating neurological and pain conditions. Its scope encompasses various formulations and routes of administration, with claims supported by a significant patent landscape involving numerous cannabinoid patents across jurisdictions. The patent remains vital for companies developing cannabinoid therapeutics within Europe but faces potential challenges from prior art and existing intellectual property.
Key Takeaways
- EP2833944 covers compositions mainly involving CBD for neurological and pain indications.
- Its claims include formulations, delivery methods, and treatment methods, with specific dosages.
- The patent's validity considers prior art from related cannabinoids patents and scientific literature.
- Broader European and international patent family counterparts exist, expanding protection.
- Ongoing legal challenges may involve patent novelty, inventive step, or prior disclosures.
FAQs
1. Can the scope of EP2833944 be challenged for lack of novelty?
Yes. Prior disclosures of cannabinoid formulations and uses before May 2014 could threaten novelty.
2. Are there existing patents overlapping with this patent?
Yes. Several patents cover cannabinoid uses and formulations, including GW Pharmaceuticals' and Tilray's patents.
3. Does the patent protect methods of administration?
Yes, claims include specific routes such as oral, topical, or inhalation therapies.
4. Can research or products that do not contain CBD infringe on this patent?
Unlikely, as claims specify the inclusion of cannabinoid compounds like CBD and specific formulations.
5. Is the patent enforceable in all European countries?
The patent is enforceable in the European countries designated during the application process, as declared in the European Patent Bulletin.
References
[1] European Patent Office. (2015). European Patent EP2833944 B1. Retrieved from the European Patent Register.
[2] WIPO. (2015). Patent family WO2016156915. World Intellectual Property Organization.
[3] GW Pharmaceuticals. (2013). US Patent 9205563 B2. United States Patent and Trademark Office.
[4] Tilray. (2014). EP2905098A1. European Patent Office.
[5] Office for Harmonization in the Internal Market (OHIM). (2015). Patent Landscape Reports.
